908 Devices (NASDAQ:MASS – Get Free Report) and Hyperfine (NASDAQ:HYPR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
Insider & Institutional Ownership
88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 15.0% of Hyperfine shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares 908 Devices and Hyperfine’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 908 Devices | -62.40% | -14.03% | -10.40% |
| Hyperfine | -226.88% | -98.83% | -67.09% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 908 Devices | $56.20 million | 5.95 | $19.49 million | ($1.00) | -8.84 |
| Hyperfine | $11.40 million | 13.93 | -$35.57 million | ($0.41) | -3.90 |
908 Devices has higher revenue and earnings than Hyperfine. 908 Devices is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for 908 Devices and Hyperfine, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 908 Devices | 1 | 0 | 1 | 0 | 2.00 |
| Hyperfine | 1 | 2 | 3 | 0 | 2.33 |
908 Devices presently has a consensus target price of $12.00, indicating a potential upside of 35.75%. Hyperfine has a consensus target price of $1.78, indicating a potential upside of 11.46%. Given 908 Devices’ higher possible upside, analysts plainly believe 908 Devices is more favorable than Hyperfine.
Risk & Volatility
908 Devices has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Summary
908 Devices beats Hyperfine on 8 of the 14 factors compared between the two stocks.
About 908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
